2-亚甲基戊二酸 | 3621-79-2

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 中文名称: 2-亚甲基戊二酸
• 英文名称: 2-methyleneglutaric acid
• 英文别名: α-Methyleneglutaric acid；2-Methylen-glutarsaeure；α-Methylen-glutarsaeure；2-methylenepentanedioic acid；2-methylideneglutaric acid；Hydron;2-methylidenepentanedioate
• CAS: 3621-79-2
• 化学式: C₆H₈O₄
• mdl: MFCD06208028
• 分子量: 144.127
• InChiKey: CWNNYYIZGGDCHS-UHFFFAOYSA-N

物化性质

• 熔点：
  130 °C
• 沸点：
  387.3±25.0 °C(Predicted)
• 密度：
  1.290±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  10
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  74.6
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2917190090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 2-Methyleneglutaric acid
Synonyms: 2-Methylidenepentanedioic acid

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 2-Methyleneglutaric acid
CAS number: 3621-79-2

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, under −20◦C.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C6H8O4
Molecular weight: 144.1

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2-亚甲基戊二酸 在 RuCl2(1,3-dimesityl-imidazolidin-2-yl)(PCy3)(=CHPh) 、 对甲苯磺酸一水合物 、 potassium carbonate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 水 、 1,2-二氯乙烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 68.0h， 生成 3-(2-氧代-5H-呋喃-3-基)丙酸
  参考文献：
  名称：

  A catalytic approach to the MH-031 lactone: application to the synthesis of geralcin analogs

  摘要：

  A concise, 5-step synthesis of the hepatoprotective lactone MH-031 was achieved. Our approach utilizes several catalytic processes, namely, a Rauhut-Currier reaction, a chemoselective Fisher esterification, and a ring closing metathesis. Further elaboration of this lactone yielded the hydrazide natural product geralcin A and dihydrogeralcin B, a saturated analog of geralcin B. Biological evaluation of the latter indicated that the presence of the enehydrazide moiety in geralcin B is critical for anticancer activity. Published by Elsevier Ltd.

  DOI：

  10.1016/j.tetlet.2014.09.088
• 作为产物：
  描述：

  环丙烷-1,1,2-三羧酸 在 vitamin B₁₂s sodium hydroxide 、 水 、 双氧水 、 三溴化磷 、 三乙基硼氢化锂 、 乙酰氯 作用下， 以 乙醚 、 水 为溶剂， 反应 89.42h， 生成 2-亚甲基戊二酸
  参考文献：
  名称：

  辅酶B 12依赖的衣康酸甲酯⇌α-亚甲基戊二酸酯模型重排反应的Carbon-13标记研究和潜在的环丙烷中间体的检查

  摘要：

  用碳13标记进行了模拟重排的模型重排，该重排模拟了依赖于辅酶B 12的酶催化的α-亚甲基戊二酸与甲氧代酸的相互转化。毫无疑问，该实验证明丙烯酸酯基团是模型中的迁移基团，就像在酶催化的重排中一样。还描述了旨在探测模型重排中可能存在的环丙基甲基中间体的实验。为此，从常见的前体环丙烷-1,1,2-三羧酸（13）开始制备顺式和反式-溴甲基环丙烷二酸（16a）和（20a）。因此，（13）被转化为酸酐（14），然后将其还原为内酯（15）。用在乙酸中的HBr打开内酯，得到所需的反式-二酸（16a）。对于顺式二酸（20a），将酸酐（14）水解，用重氮甲烷酯化，然后用三乙基硼氢化锂还原。用三溴化磷将所得的醇（19）转化为溴化物（20a）。一系列广泛的实验，涉及用维生素B 12S处理酸及其甲基和四氢吡喃基酯进行了。在任何反应混合物中均未检测到甲基衣康酸（3a）。然而，观察到α-亚甲基戊二酸（2a）和甲基戊二酸（21）作为反应产物。甲基甲苯p

  DOI：

  10.1039/p29880000061

文献信息

• [EN] C7-SUBSTITUTED CAMPTOTHECIN ANALOGS<br/>[FR] ANALOGUES DE CAMPTOTHÉCINE SUBSTITUÉS EN C7
  申请人：BIONUMERIK PHARMACEUTICALS INC

  公开号：WO2009051580A1

  公开（公告）日：2009-04-23

  The novel C7-modified camptothecin analogs, and pharmaceutically-acceptable salts thereof, of the present invention: (i) possess potent antitumor activity (i.e., in nanomolar or subnanomolar concentrations) for inhibiting the growth of human and animal tumor cells in vitro; (ii) are potent inhibition of Topoisomerase I; (iii) lack of susceptibility to MDR/MRP drug resistance; (iv) require no metabolic drug activation: (v) lack glucuronidation of the A-ring or B- ring; (vi) reduce drug-binding affinity to plasma proteins; (vii) maintain lactone stability; (viii) maintain drug potency; and (ix) possess a low molecular weight (e.g., MW<600).

  本发明的C7-修饰紫杉醇类似物及其药用盐具有以下特点：(i) 在体外对人类和动物肿瘤细胞的生长具有强大的抗肿瘤活性（即在纳摩尔或亚纳摩尔浓度下）；(ii) 对拓扑异构酶I有强大的抑制作用；(iii) 不易受到MDR/MRP药物耐药性的影响；(iv) 无需代谢激活；(v) 不发生A环或B环的葡萄糖醛酸化；(vi) 减少药物与血浆蛋白的结合亲和力；(vii) 保持内酯的稳定性；(viii) 保持药物的效力；以及(ix) 具有较低的分子量（例如，分子量<600）。
• [EN] PROSTATE SPECIFIC MEMBRANE ANTIGEN INHIBITORS<br/>[FR] INHIBITEURS D'ANTIGÈNES MEMBRANAIRES SPÉCIFIQUES DE LA PROSTATE
  申请人：BAYER SCHERING PHARMA AG

  公开号：WO2011073286A1

  公开（公告）日：2011-06-23

  This invention relates to novel compounds suitable for labelling by 18F and the corresponding 18F labelled compounds themselves, 19F-fluorinated analogues thereof and their use as reference standards, methods of preparing such compounds, compositions comprising such compounds, kits comprising such compounds or compositions and uses of such compounds, compositions or kits for diagnostic imaging by positron emission tomography (PET).

  这项发明涉及适合用18F标记的新化合物，以及相应的18F标记化合物本身，其19F-氟化类似物及其作为参考标准的用途，制备这种化合物的方法，包含这种化合物的组合物，包含这种化合物或组合物的试剂盒以及用于正电子发射断层扫描（PET）的这种化合物、组合物或试剂盒的用途。
• METHOD FOR PREPARING QUATERNARY PHOSPHONIUM SALTS
  申请人：Microvast Power Systems Co.,Ltd.

  公开号：US20150166587A1

  公开（公告）日：2015-06-18

  A two-step pathway for preparing high pure quaternary phosphonium salts is disclosed. In the first step, hydrogen phosphide (PH 3 ) or a higher phophine reacts with a protonic compound to produce a phosphonium salt, which then reacts with a carbonic acid diester to produce a quaternary phosphonium salt in the second step. On one hand, hydrogen phosphide (PH 3 ) and higher phophines, including primary phosphines, secondary phosphines, and tertiary phosphines, after neutralization with protonic compound, become sufficiently reactive and can be alkylated by carbonic acid diester to form quaternary phosphonium cations. On the other hand, as an anion-exchange procedure is completely avoided, the process not only gives quaternary phosphonium salts of high purity, but also gives people freedom to design the cation and the anion of a quaternary phosphonium salt synchronously by choosing a preferred phosphine and a protonic compound that can supply a desired anion.

  揭示了一种制备高纯度四元磷铵盐的两步途径。在第一步中，氢磷化物（PH3）或更高的磷化物与质子化合物发生反应，产生磷铵盐，然后在第二步中与碳酸二酯发生反应，产生四元磷铵盐。一方面，氢磷化物（PH3）和更高的磷化物，包括一次磷化物、二次磷化物和三次磷化物，在与质子化合物中和后变得足够活性，可以被碳酸二酯烷基化形成四元磷铵阳离子。另一方面，由于完全避免了阴离子交换程序，该过程不仅提供高纯度的四元磷铵盐，还使人们可以通过选择理想的磷化物和可以提供所需阴离子的质子化合物，同时设计四元磷铵盐的阳离子和阴离子。
• [EN] TETRAHYDROISOQUINOLINES CONTAINING SUBSTITUTED AZOLES AS FACTOR XIA INHIBITORS<br/>[FR] TÉTRAHYDROISOQUINOLINES COMPRENANT DES AZOLES SUBSTITUÉS EN TANT QU'INHIBITEURS DU FACTEUR XIA
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2014160668A1

  公开（公告）日：2014-10-02

  The present invention provides compounds of Formula (I), or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective factor XIa inhibitors or dual inhibitors of FXIa and plasma kallikrein. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating thromboembolic and/or inflammatory disorders using the same.

  本发明提供了式（I）的化合物，或其立体异构体、互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性因子XIa抑制剂或FXIa和血浆激肽酶的双重抑制剂。本发明还涉及包含这些化合物的药物组合物以及使用它们治疗血栓栓塞和/或炎症性疾病的方法。
• PRODRUGS OF GUANFACINE
  申请人：Whomsley Rhys

  公开号：US20110065796A1

  公开（公告）日：2011-03-17

  Prodrugs of guanfacine with amino acids or short peptides, pharmaceutical compositions containing such prodrugs and a method for providing therapeutic benefit in the treatment of ADHD/ODD (attention deficient hyperactivity disorder and oppositional defiance disorder) with guanfacine prodrugs are provided herein. Additionally, methods for minimizing or avoiding the adverse gastrointestinal side effects associated with guanfacine administration, as well as improving the pharmacokinetics of guanfacine are provided herein.

  本文提供了具有氨基酸或短肽的瓜那非辛前药、含有这种前药的药物组合物以及一种利用瓜那非辛前药在治疗注意力缺陷多动障碍/反抗性违抗障碍（ADHD/ODD）中提供治疗益处的方法。此外，本文还提供了减少或避免与瓜那非辛给药相关的不良胃肠道副作用的方法，以及改善瓜那非辛的药代动力学的方法。